The Connected Aging Lab is committed to advancing brain health and emotional well-being in older adults by developing inclusive, relationship-centered interventions that bridge science, clinical care, and community.

The Neuro-Oncology Translational Research Laboratory studies primary brain tumors from pure basic science through the continuum to clinical trials. 

Our work advocates for the wider adoption of alteplase, antiplatelet therapy in ischemic stroke, secondary stroke prevention, off-label guidelines for those with acute ischemic stroke, and more.

Our mission is to design and develop original devices, software solutions, and combined unique methodologies that translate into discoveries for next generation care.

Our mission is to advance biomedical knowledge in Multiple Sclerosis and support investigators in Neurology using best practices and comprehensive biostatistics expertise.

Our lab specializes in clinical and research informatics, with a diverse portfolio of projects that leverage electronic health record (EHR) data and multimodal research data to enhance clinical care and advance research in the neurosciences.

The BraNiC lab is dedicated to developing advanced methods for assessing the potential for brain function recovery after severe brain injuries.

The Calvier Lab's research focuses on endothelial modulation as a therapeutic approach to inflammatory diseases.

The Ishii Laboratory is interested in understanding the bidirectional relationship between brain function and systemic metabolism with an emphasis on metabolic deficits in Alzheimer’s disease and how it differs from normal aging. Our laboratory focuses on generating hypotheses derived from open questions in clinical neurology and neuroendocrinology, testing these hypotheses using molecular genetics and neuroscience techniques in the laboratory, and whenever possible verifying these findings in clinically relevant human research studies. 

The Noch Lab is a basic and translational research laboratory focused on identifying novel strategies to target metabolic vulnerabilities in glioma.